The All of Us Research Program is a key element of the Precision Medicine Initiative (PMI). Through advances in research, technology, and policies that empower patients, the PMI will enable a new era of medicine in which researchers, health care providers, and patients work together to develop individualized care. The All of Us Research Program is a historic effort to gather data from one million or more people living in the United States to accelerate research and improve health. By taking into account individual differences in lifestyle, environment, and biology, researchers will uncover paths toward delivering precision medicine.
The Participant Technology Systems Center (PTSC) develops applications and websites for volunteers to enroll in the program, provide data, and receive updates. The center also supports ongoing testing and upgrades to improve the user experience, implements innovative participant tools, and ensures the security of all participant-facing systems. SP1 provides an approach to engage, encourage, motivate, retain and sustain a nationally representative cohort of 1M+ participants, who will be monitored for 10 or more years. SP1 uses current technologies such as mobile phones, website and feature phones to achieve the objectives of the All of Us Cohort Program as well as allow for evolving consumer technologies such as wireless sensors, wearables and evolving science that balance innovation with robustness and scalability.
While the All of Us program has been testing mHealth biomarkers of sleep, daily activity, and heart rate using commercially available wearables such as Fitbit activity trackers in a subset of its cohort, new sensor-derived biomarkers from TR&D3, in particular, stress, pain flares, and participant engagement scores obtained from TR&D1 are of interest to the All of Us cohort. Moreover, the rich sensor data being continually collected in order to compute the biomarkers cannot be anonymized easily and present significant privacy concerns to participants. PTSC can use privacy management tools from TR&D3 (Aim 3) for optimization of privacy-utility trade-offs before participant data is released for third party research. A successful pilot deployment can lead to the deployment of these and other novel biomarkers and privacy management techniques in a larger subset of the All of Us cohort, and advance precision medicine.